A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2

By sjmartinez • February 27, 2024

Paules CI, Wang J, Tomashek KM, Bonnett T, Singh K, Marconi VC, Davey RT Jr, Lye DC, Dodd LE, Yang OO, Benson CA, Deye GA, Doernberg SB, Hynes NA, Grossberg R, Wolfe CR, Nayak SU, Short WR, Voell J, Potter GE, Rapaka RR. A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2. Ann Intern Med. 2024 Feb 27. doi: 10.7326/M23-2593. Epub ahead of print. PMID: 38408357.

Tags: Infectious Diseases, Publications

Structure, identification and characterization of the RibD-enolase complex in Francisella

Liu X, Clemens DL, Lee BY, Aguirre R, Horwitz MA, Zhou ZH. Structure, identification and characterization of the RibD-enolase complex in Francisella. Protein Cell. 2025[...]

Cardiac Implantable Device Infection Surveillance Algorithm

Mull HJ, Golenbock SW, Basnet Thapa D, Shin MH, Harvey KL, Lamkin RP, Strymish J, Branch-Elliman W. Cardiac Implantable Device Infection Surveillance Algorithm. JAMA Netw[...]

No Evidence of Anti-Influenza Nucleoprotein Antibodies in Retail Milk from Across Canada (April-July 2024)

Wallace HL, Wight J, Rzeszutek GJ, Jafri MS, Baz M, Dowding B, Flamand L, Hobman T, Jean F, Joy JB, Lang AS, MacParland S, McCormick[...]